Patents Issued in October 12, 2017
  • Altering Gene Expression in Modified T Cells and Uses Thereof
    Publication number: 20170290858
    Abstract: The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR ? chain, TCR ? chain, beta-2 microglobulin and FAS further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.
    Type: Application
    Filed: October 15, 2015
    Publication date: October 12, 2017
    Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Yangbing ZHAO, Jiangtao REN, Xiaojun LIU, Carl H. JUNE
  • Novel Mensenchymal Stem Cells And Bone-Forming Cells
    Publication number: 20170290859
    Abstract: The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.
    Type: Application
    Filed: May 7, 2017
    Publication date: October 12, 2017
    Inventors: Cindy Badoer, Enrico Bastianelli, Xavier Pesesse
  • CARDIOSPHERE-DERIVED CELLS AND EXOSOMES SECRETED BY SUCH CELLS IN THE TREATMENT OF MUSCULAR DYSTROPHY
    Publication number: 20170290860
    Abstract: Described herein are compositions and techniques related to generation and therapeutic application of cardiosphere-derived cells (CDCs) and CDC-derived exosomes. These cells and their secreted vesicles contain a unique milieu of biological factors, including cytokines, growth factors, transcription factors, nucleic acids including non-coding nucleic acids such as microRNAs, that serve to initiate and promote many therapeutic effects. Exosomes and their “cargo” contents, such as microRNAs can favorably modulate apoptosis, inflammation and fibrosis in the injured heart. Thus, CDC-derived exosomes represent a novel “cell-free” therapeutic candidate for tissue repair.
    Type: Application
    Filed: October 2, 2015
    Publication date: October 12, 2017
    Applicant: Cedars-Sinai Medical Center
    Inventors: Eduardo Marban, Mark Amin Aminzadeh
  • TREATMENT OF DIABETIC FOOT ULCER USING PLACENTAL STEM CELLS
    Publication number: 20170290861
    Abstract: Provided herein are methods of using tissue culture plastic-adherent placental cells, e.g. placental stem cells, in the treatment of diabetic foot ulcer (DFU).
    Type: Application
    Filed: September 25, 2015
    Publication date: October 12, 2017
    Applicant: Anthrogenesis Corporation
    Inventors: Steven A. FISCHKOFF, Denesh CHITKARA, Uri HERZBERG, Vladimir JANKOVIC
  • Cytotherapeutics, cytotherapeutic units and methods for treatments using them
    Publication number: 20170290862
    Abstract: The present invention provides cytotherapeutic units comprising predetermined numbers of selected types of potent cells. Assurance of the nature and identities of such cells is achieved through assay and certification of said numbers and identities. Therapeutic modalities are provided. Libraries of cell preparations with assayed and preferably certified populations are preferred and the preparation of cell preparations tailored to specific patients or disease states are provided.
    Type: Application
    Filed: November 28, 2016
    Publication date: October 12, 2017
    Applicant: Anthrogenesis
    Inventor: Robert J. HARIRI
  • ENDOMETRIAL STEM CELLS AND METHODS OF MAKING AND USING SAME
    Publication number: 20170290863
    Abstract: The invention provides pluripotent stem cells and methods for making and using pluripotent stem cells. Pluripotent stem cells, among other things, can differentiate into various cell lineages in vitro, ex vivo and in vivo. Pluripotent stem cells, among other things, can also be used to produce conditioned medium.
    Type: Application
    Filed: February 17, 2017
    Publication date: October 12, 2017
    Applicant: XON Cells, Inc.
    Inventors: Thomas E. Ichim, Xiaolong Meng, Neil H. Riordan
  • MESENCHYMAL-LIKE STEM CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS, METHODS AND USES THEREOF
    Publication number: 20170290864
    Abstract: The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically, T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 12, 2017
    Inventors: Xiaofang WANG, Ren-He XU
  • Therapeutic Compositions and Uses Thereof
    Publication number: 20170290865
    Abstract: This invention provides pharmaceutical compositions, including anti-gastrointestinal cancer compositions, containing propolis and cyclodextrin. Methods of using such compositions, in particular in the treatment or prevention of gastrointestinal cancers, and the resensitisation of gastrointestinal cancers to therapy are also provided.
    Type: Application
    Filed: March 21, 2017
    Publication date: October 12, 2017
    Applicant: Manuka Health New Zealand Limited
    Inventors: Kerry PAUL, Owen John CATCHPOLE, Darina LAZAROVA
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF WOUNDS, DISORDERS, AND DISEASES OF THE SKIN
    Publication number: 20170290866
    Abstract: The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.
    Type: Application
    Filed: December 28, 2016
    Publication date: October 12, 2017
    Inventors: Suma KRISHNAN, Pooja AGARWAL
  • EQUINE PARASITE TREATMENT METHODS AND COMPOSITIONS
    Publication number: 20170290867
    Abstract: New compositions and methods are provided for controlling a parasitic infection in a horse through administration of an effective amount of D. flagrans. In certain aspects, multiple, distinct strains of D. flagrans are administered. In additional aspects, the amount and treatment regimen of D. flagrans administered to a horse is based on one or more pre-identified characteristics of the horse, is combined with additional therapeutic agents for more comprehensive parasite control, or is accomplished via custom made, pre-measured daily dose packages. In another aspect, compositions and methods are provided that comprise combined use of 1) D. flagrans and 2) one or more insect growth regulators.
    Type: Application
    Filed: April 7, 2017
    Publication date: October 12, 2017
    Inventors: Casey Fleming, Lydia Gray, Paal Gisholt
  • METHOD OF PREPARING AKEBIA QUINATA EXTRACT AND FUNCTIONAL FOOD USING THE SAME
    Publication number: 20170290868
    Abstract: Provided are a method of extracting saponin which is the physiologically active component of akebia quinata with high efficiency, by sequentially subjecting to a) adding akebia quinata flesh to akebia quinata seeds and performing aging; and b) extracting with alcohol, a method of further improving saponin extraction efficiency by adding ginger, and a food composition containing the extract produced by this method. Higher added value may be created by improving the saponin extraction efficiency from akebia quinata seeds using akebia quinata flesh which has not been utilized when extracting saponin.
    Type: Application
    Filed: March 21, 2017
    Publication date: October 12, 2017
    Inventor: Song Bae KIM
  • EXTRACTION OF PHARMACEUTICALLY ACTIVE COMPONENTS FROM PLANT MATERIALS
    Publication number: 20170290869
    Abstract: The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS of given purity, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from cannabis.
    Type: Application
    Filed: March 23, 2017
    Publication date: October 12, 2017
    Applicant: GW Pharma Limited
    Inventors: Brian Anthony Whittle, Colin A. Hill, Ian R. Flockhart, David Victor Downs, Peter Gibson, Gary William Wheatley
  • INGESTIBLE FILMS HAVING SUBSTANCES FROM HEMP OR CANNABIS
    Publication number: 20170290870
    Abstract: Films that are mucosally dissolvable, and containing a matrix and one or more active agents from hemp or cannabis within the matrix, are provided. The disclosure also provides methods for preparing such a film for pharmaceutical and nutraceutical applications.
    Type: Application
    Filed: April 12, 2017
    Publication date: October 12, 2017
    Inventor: Scott Schaneville
  • METHOD OF TREATING HYPERTENSION
    Publication number: 20170290871
    Abstract: A method of treating hypertension can include administering to a patient in need thereof a therapeutically effective amount of an extract of Matricaria chamomilla L. The extract can be administered orally to the patient in an amount of about 100 mg/kg to about 200 mg/kg.
    Type: Application
    Filed: April 11, 2016
    Publication date: October 12, 2017
    Inventors: AMANI SHAFEEK AWAAD, GHADA MOHAMED ZAIN, REHAM M. EL-MELIGY, AMAL AHMED SAFHI, VIDYA DEVENATHADESIKAN SESHADRI, SHEKHAH SAUD ALMOQREN, NOURAH AHMED AN QURAIN
  • ORAL SPRAY CONTAINING IXERIS DENTATA NAKAI EXTRACT AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING XEROSTOMIA CAUSED BY DIABETES
    Publication number: 20170290872
    Abstract: An oral spray formulation using an Ixeris dentata Nakai extract as an active ingredient of a composition for preventing and treating xerostomia occurring as a diabetic complication, particularly an oral spray formulation capable of administering a drug through a simple and rapidly absorbable route is provided. The secretion of saliva is reduced as cells from a submandibular gland tissue of a diabetes model animal are destroyed. However, when the Ixeris dentata Nakai extract of the present invention is sublingually sprayed into a sublingual region of the diabetes model animal, expression levels of ?-amylase, AQP5 and NHE1 can significantly increase, resulting in an increased secretion quantity and rate of saliva.
    Type: Application
    Filed: February 23, 2017
    Publication date: October 12, 2017
    Applicants: INDUSTRIAL COOPERATION FOUNDATION CHONBUK NATIONAL UNIVERSITY, Daegu Gyeongbuk Institute of Science and Technology, REPUBLIC OF KOREA (MANAGEMENT: RURAL DEVELOPMENT ADMINISTRATION), INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Han Jung CHAE, Hyung-Ryong KIM, Seung Hyun KIM, Sang Won LEE
  • Method Of Using Homeopathic Kit Containing Gel, Rinse And Spray For Management Of Post-Oral Surgical Recovery And Maintenance Of Oral Health
    Publication number: 20170290873
    Abstract: Methods of maintaining general oral care as well as reducing inflammation, pain and bruising after oral surgery with a homeopathic recovery kit are disclosed.
    Type: Application
    Filed: April 8, 2016
    Publication date: October 12, 2017
    Applicant: Stellalife
    Inventor: Walter Tatch
  • COMPOSITION FOR PREVENTING OR TREATING HYPERLIPIDEMIA
    Publication number: 20170290874
    Abstract: A pharmaceutical composition for preventing or treating hyperlipidemia includes a Salvia miltiorrhiza extract, a Crataegus pinnatifida extract, a Polygonum multiflorum extract, and a Ligusticum chuanxiong extract, thereby reducing the amounts of serum cholesterol and LDL-cholesterol and increasing the amount of HDL-cholesterol; significantly reduces the amount of serum triglyceride compared with existing statin-based drugs, thereby exhibiting prophylactic and therapeutic effects of hyperlipidemia with various symptoms even without the co-administration of other drugs; and reduces the amounts of hepatic cholesterol and triglyceride, thereby exhibiting an effect of inhibiting fatty liver.
    Type: Application
    Filed: May 27, 2015
    Publication date: October 12, 2017
    Inventors: Dae-Ho KOOH, Sung-Kew KIM, Young-Chan BAIK, Young-Bong SHIN, Myoung Seok KIM
  • SYNERGISTIC COMPOSITION FOR OSTEOARTHRITIS
    Publication number: 20170290875
    Abstract: The present invention relates to synergistic compositions for the treatment of one or more associated conditions of arthritis or rheumatoid arthritis osteoarthritis. More particularly, novel synergistic compositions which comprises a combination of therapeutically effective amounts of: a) an alcoholic/hydroalcoholic extract of Tamarindus indica seed comprising proanthocyanidins either alone or in combination with water extract of Tamarindus indica seed comprising polysaccharides, b) a Curcuma longa rhizome extract comprising curcuminoids, c) optionally containing pharmaceutically or nutraceutically or dietetically acceptable carriers/excipients. The invention also relates to a method of treating one or more associated conditions of arthritis or rheumatoid arthritis or osteoarthritis using synergistic composition.
    Type: Application
    Filed: October 9, 2015
    Publication date: October 12, 2017
    Inventors: Ganga Raju GOKARAJU, Rama Raju GOKARAJU, Venkata Kanaka Ranga Raju GOKARAJU, Trimurtulu GOLAKATI, Kiran BHUPATHIRAJU
  • COMPOSITIONS AND METHODS FOR LONG ACTING PROTEINS
    Publication number: 20170290876
    Abstract: The present invention is based, in part, on the discovery of peptide tags that increase the half-life and/or mean residence time of proteins or nucleic acids in the eye. In certain aspects the invention peptide tags increase the half-life and/or mean residence time of antibodies and antigen binding fragments, therapeutic proteins, protein receptors, DARPins and/or aptamers in the eye.
    Type: Application
    Filed: June 24, 2015
    Publication date: October 12, 2017
    Applicant: Novartis AG
    Inventors: Joy GHOSH, Michael ROGUSKA, Andrew Anh NGUYEN, Thomas PIETZONKA, Stephen Hedrick POOR, Matthias MACHACEK, Chad Eric BIGELOW
  • Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Various Diseases
    Publication number: 20170290877
    Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of various diseases or disorders strongly related to JNK signaling.
    Type: Application
    Filed: October 8, 2015
    Publication date: October 12, 2017
    Inventors: Jean-Marc Combette, Catherine Deloche
  • METHODS OF TREATING CANCER WITH TUBULYSIN CONJUGATES
    Publication number: 20170290878
    Abstract: The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating folate receptor-expressing cancers with a folate-tubulysin conjugate. The invention described herein also relates to methods of treating folate-expressing cancers with a folate tubulysin conjugate in patients where stable disease results after treatment with the folate-tubulysin conjugate.
    Type: Application
    Filed: September 24, 2015
    Publication date: October 12, 2017
    Inventors: Christopher Paul LEAMON, Joseph Anand REDDY, Binh NGUYEN, Alicia BLOOMFIELD, Melissa NELSON, Ryan DORTON
  • METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
    Publication number: 20170290879
    Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
    Type: Application
    Filed: January 13, 2017
    Publication date: October 12, 2017
    Applicant: Ferring B.V.
    Inventors: Tine Kold Olesen, Bo-Eric Persson, Per Cantor, Egbert A. van der Meulen, Jens-Kristian Slott Jensen
  • VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION
    Publication number: 20170290880
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Application
    Filed: May 26, 2017
    Publication date: October 12, 2017
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION
    Publication number: 20170290881
    Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
    Type: Application
    Filed: June 2, 2017
    Publication date: October 12, 2017
    Inventors: Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi
  • Specific Combined Therapy of Malignant Tumors with a Cytostatic and Its Modifier
    Publication number: 20170290882
    Abstract: The invention relates to medicine, particularly, to treating patients with malignant tumors using the combination of cytostatic and biotherapy. Method for treating malignant hematological diseases or melanoma in subjects by applying one or more cytostatics impacting DNA in combination with N-acetyl-D-glucosaminyl-?-(1-4)-N-acetylmuramyl-L-alanyl-D-glutamic acid (GMDP-A) according to the following therapeutic sequence for subjects: Intravenous injection of ¼to ½standard therapeutic dose of the cytostatic selected for this type of subjects; Then, after cytostatic administration, the first injection of N-acetyl-D-glucosaminyl-?-(1-4)-N-acetylmuramyl-L-alanyl-D-glutamic acid (GMDP-A) in effective amount set forth for these subjects; GMDP-A repeated injections in effective amount set forth for selected subjects.
    Type: Application
    Filed: November 23, 2015
    Publication date: October 12, 2017
    Inventors: Tatyana Mikhaylovna Andronova, Raisa Ivanovna Yakubovskaya, Elena Romanovna Nemtsova, Evgeniya Ivanovna Nesterova
  • VASCULAR DISRUPTION AGENTS AND USES THEREOF
    Publication number: 20170290883
    Abstract: Uses of Apo2L/TRAIL polypeptides and death receptor agonist antibodies to disrupt tumor associated vasculature are provided. Methods of treating cancer in mammals, kits, and articles of manufacture are also provided.
    Type: Application
    Filed: November 18, 2016
    Publication date: October 12, 2017
    Applicant: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • COMPOSITIONS AND METHODS FOR DENGUE VIRUS CHIMERIC CONSTRUCTS IN VACCINES
    Publication number: 20170290884
    Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.
    Type: Application
    Filed: April 20, 2017
    Publication date: October 12, 2017
    Inventors: Dan T. Stinchcomb, Claire Kinney, Richard M. Kinney, Jill A. Livengood
  • A METHOD OF TREATING JOINT DISEASE
    Publication number: 20170290885
    Abstract: The invention relates to a method for treating joint inflammation. More particularly, the invention relates to a method for treating joint disease involving the inhibition or inactivation of growth differentiation factor 15 (GDF15) in an individual.
    Type: Application
    Filed: September 29, 2015
    Publication date: October 12, 2017
    Inventors: Dirk ELEWAUT, Stijn LAMBRECHT
  • TREATMENT OF NEURODEVELOPMENTAL DISORDERS
    Publication number: 20170290886
    Abstract: Disclosed herein are methods for treating a neurodevelopmental disorder in a subject in need thereof. The method includes administering to the subject in need thereof an effective amount of a methyl-CpG-binding protein 2 (MeCP2) or a nucleic acid encoding the MeCP2 to alleviate or ameliorate the symptoms associated with the neurodevelopmental disorder. According to preferred embodiments, the MeCP2 has one or more post-translational modifications that result in increased levels of sumoylation, phosphorylation or both, as compared with that of the endogenous MeCP2 in the subject.
    Type: Application
    Filed: April 5, 2017
    Publication date: October 12, 2017
    Inventors: Eminy H.Y. LEE, Derek Jui-Cheng TAI, Yen-Chen LIU, Wei-Lun HSU
  • CELL BASED THERAPY FOR FEMALE SEXUAL DYSFUNCTION
    Publication number: 20170290887
    Abstract: Disclosed are compositions of matter, therapeutic means, and methods of use for the treatment of female sexual dysfunction associated with vasculogenic degeneration.
    Type: Application
    Filed: April 6, 2017
    Publication date: October 12, 2017
    Inventors: Thomas Ichim, Amit Patel
  • Compositions and Methods for Treating Inflammatory Conditions of the Ocular Surface
    Publication number: 20170290888
    Abstract: This application discloses ophthalmic formulations and methods for treating inflammatory disease and conditions of the ocular surface with one or more C-C chemokine receptor type 7 (CCR7) antagonists. The compositions may be formulated for subconjunctival or topical administration to the eye and are effective in the treatment of inflammatory disease and conditions of the ocular surface.
    Type: Application
    Filed: April 24, 2017
    Publication date: October 12, 2017
    Inventors: Reza Dana, Daniel Saban
  • METHODS AND COMPOSITIONS FOR TREATING DYSBIOSIS AND GASTROINTESTINAL AND INFLAMMATORY DISORDERS
    Publication number: 20170290889
    Abstract: The present invention relates to the use of type 2 cytokines and mucins for increasing the amount or activity of bacterial species of the Clostridia class in the gastrointestinal tract, for treating dysbiosis in the gastrointestinal tract, for treating gastrointestinal and inflammatory disorders, and for promoting wound healing in the gastrointestinal tract.
    Type: Application
    Filed: April 11, 2017
    Publication date: October 12, 2017
    Applicant: New York University
    Inventors: P'ng Loke, Kenneth Cadwell, Deepshika Ramanan, Rowann Bowcutt
  • STIMULATION OF OVARIAN FOLLICLE DEVELOPMENT AND OOCYTE MATURATION
    Publication number: 20170290890
    Abstract: Methods are provided for stimulating ovarian follicles in a mammal through activation of the mTor signaling pathway.
    Type: Application
    Filed: September 9, 2015
    Publication date: October 12, 2017
    Inventors: Yuan Cheng, Aaron J.W. Hsueh
  • METHOD OF BONE REGENERATION OR BONE AUGMENTATION
    Publication number: 20170290891
    Abstract: The present invention provides a means effective for bone regeneration or bone augmentation. Provided is a method of bone regeneration or bone augmentation, comprising: implanting a porous composite at a site in need of the bone regeneration or bone augmentation, and administering parathyroid hormone (PTH) to a subject in need of the bone regeneration or bone augmentation, wherein the porous composite comprises calcium phosphate.
    Type: Application
    Filed: April 8, 2016
    Publication date: October 12, 2017
    Applicant: TOYOBO CO., LTD.
    Inventors: Shinji Kamakura, Satoru Nakajou, Atsushi Iwai, Fumihiko Kajii, Hidenori Tanaka
  • POLYMERIC ENKEPHALIN PRODRUGS
    Publication number: 20170290892
    Abstract: The unique polymeric OGF and enkephalin peptide conjugates with large size polymer attached at the C-terminus through hydrolysable linkage enhancing therapeutic properties of OGF and enkephalin peptides.
    Type: Application
    Filed: July 14, 2015
    Publication date: October 12, 2017
    Applicant: PEG BIOSCIENCES, INC.
    Inventor: Chyi LEE
  • TREATMENT OF INFECTION BY HUMAN ENTEROVIRUS D68
    Publication number: 20170290893
    Abstract: The present disclosure provides compositions and methods for treating an infection by EV-D68. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by EV-D68.
    Type: Application
    Filed: September 17, 2015
    Publication date: October 12, 2017
    Inventor: Ronald D. Moss
  • COMPOSITIONS AND METHODS FOR TREATING THYROID DISEASE
    Publication number: 20170290894
    Abstract: The present disclosure relates to a compound and method of using such compound, preferably in the form of a dietary supplement that, when administered, is capable of treating thyroid disease and various thyroid-related disorders, such as Hashimoto's thyroiditis. The unique combination of the composition is preferably administered orally via acid resistant or enteric-coated capsule, soft gel or tablet. The composition is preferably comprised of at least Catalase, Reduced Glutathione, Acetylated Glutathione, DPP-IV protease enzyme, Pepsin, Bromelain, Pancreatin, Vitamin D, and Selenium. The composition can further comprise a palliative agent, and can be provided in specific dosages or administered in forms besides those listed above.
    Type: Application
    Filed: April 4, 2017
    Publication date: October 12, 2017
    Applicant: SCRIPT ESSENTIALS, LLC
    Inventor: Suzy Cohen
  • HEARTWORM VACCINE, METHODS AND USES THEREOF
    Publication number: 20170290895
    Abstract: The present invention encompasses a vaccine composition and method of use for treating heartworm infestation in mammals. The vaccine composition includes chimeric antigens engineered and manufactured using the genetic code (i.e., the amino acid or protein sequence) of the target sequence. After introduction of the vaccine composition containing the target antigen into the host (e.g., a canine), the host will generate antibodies as part of its robust immune response to the antigen. As the antibodies circulate through the host's plasma, heartworm larvae will consume the antibodies as they feed on the plasma. The antibodies will then act on internal targets of the worm recognized as antigens.
    Type: Application
    Filed: April 5, 2017
    Publication date: October 12, 2017
    Applicant: MERIAL INC.
    Inventor: Laurent Fischer
  • MULTICOMPONENT OR MONOCOMPONENT VACCINE TO BE USED AGAINST CHAGAS DISEASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE FOR THE OBTENTION OF IMMUNOGEN OF SAID VACCINES, AND NUCLEIC ACID USED IN SAID PROCEDURE
    Publication number: 20170290896
    Abstract: A monocomponent vaccine effective to moderate the clinical consequences of Chages disease, capable of stimulating an immune response against the trans-sialidase virulence factor of the Trypanosoma cruzi parasite. The vaccine active ingredient is an immunogenic component with a polynucleotide encoding one or more polypeptide(s) which includes a C-terminal region composed of at least two repetitive units of amino acids, with a polypeptide with trans-sialidase activity of Trypanosoma cruzi fused to the C-terminal region. The vaccine further comprises an aluminum oxide adjuvant that does not inhibit trans-sialidase enzymatic activity of the immunogen portion.
    Type: Application
    Filed: April 20, 2017
    Publication date: October 12, 2017
    Inventor: Carlos de Baeremaecker Barros
  • Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers
    Publication number: 20170290897
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: April 5, 2017
    Publication date: October 12, 2017
    Inventors: Andrea MAHR, Toni WEINSCHENK, Anita WIEBE, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • PRIMING OF AN IMMUNE RESPONSE
    Publication number: 20170290898
    Abstract: The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci.
    Type: Application
    Filed: April 25, 2017
    Publication date: October 12, 2017
    Applicant: University of Copenhagen
    Inventors: Peter Johannes Holst, Allan Randrup Thomsen, Jan Pravsgaard Christensen, Mirjana Grujic
  • MEANS AND METHODS FOR ACTIVE CELLULAR IMMUNOTHERAPY OF CANCER BY USING TUMOR CELLS KILLED BY HIGH HYDROSTATIC PRESSURE AND DENDRITIC CELLS
    Publication number: 20170290899
    Abstract: Disclosed are pharmaceutical compositions for inducing an immune response against tumor cells comprising tumor cells which are made apoptotic by treatment with high hydrostatic pressure and dendritic cells, and methods for producing such compositions.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 12, 2017
    Inventors: Jirina BARTÛ{hacek over (N)}KOVÁ, Radek {hacek over (S)}PÍ{hacek over (S)}EK
  • CHIMERIC ANTIGEN RECEPTOR-EXPRESSING T CELLS AS ANTI-CANCER THERAPEUTICS
    Publication number: 20170290900
    Abstract: Cytotoxic lymphocytes expressing chimeric antigen receptors (CAR) that target and bind small conjugate molecules (SCM) are disclosed, as well as methods of using the cells and the SCMs in the treatment of cancer.
    Type: Application
    Filed: October 18, 2016
    Publication date: October 12, 2017
    Inventors: Philip S. Low, Haiyan Chu, Yong Gu Lee
  • GLOBAL GENE REGULATORS (GGR) AS VACCINE CANDIDATES AGAINST PARATUBERCULOSIS
    Publication number: 20170290901
    Abstract: Described herein is a mycobacterium mutant, comprising at least one mutation in at least one gene sequence encoding global gene regulators (GGRs) selected from the group consisting of sigH, sigL, sigE, ECF-1, and mixtures thereof, wherein the GGR gene is at least partially inactivated. Described herein also is a vaccine based on the mutant and a method of differentiating between subjects that have been infected with mycobacterium and subjects that have not been infected with mycobacterium or have been vaccinated with a mycobacterium vaccine.
    Type: Application
    Filed: April 20, 2017
    Publication date: October 12, 2017
    Inventor: Adel M. Talaat
  • MULTIPLE VARIANTS OF MENINGOCOCCAL PROTEIN NMB1870
    Publication number: 20170290902
    Abstract: Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870.
    Type: Application
    Filed: November 14, 2016
    Publication date: October 12, 2017
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Maurizio COMANDUCCI, Mariagrazia PIZZA
  • Attenuated Bordetella Strains
    Publication number: 20170290903
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Application
    Filed: June 19, 2017
    Publication date: October 12, 2017
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST FILOVIRUS INFECTION
    Publication number: 20170290904
    Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
    Type: Application
    Filed: September 3, 2015
    Publication date: October 12, 2017
    Applicants: Bavarian Nordic A/S, Janssen Vaccines & Prevention B.V., The United States of America, as represented by the Secretary Department of Health and Human Ser..
    Inventors: Ariane VOLKMANN, Robin STEIGERWALD, Ulrike DIRMEIER, Maria Grazia PAU, Benoit Christophe CALLENDRET, Lucy A. WARD
  • VACCINE
    Publication number: 20170290905
    Abstract: The present invention relates to Human Rhinovirus (HRV) Virus-Like Particles (VLPs) and methods of making HRV VLPs.
    Type: Application
    Filed: September 17, 2015
    Publication date: October 12, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Cindy CASTADO, Steve LABBE, Patrick RHEAULT
  • VLPS Containing Ligands and Methods Related Thereto
    Publication number: 20170290906
    Abstract: This disclosure relates to immunogenic compositions and methods of enhancing an immune response to an antigen. In certain embodiments, the disclosure relates to virus-like carries comprising a TLR5 agonist on the exterior without an antigen.
    Type: Application
    Filed: April 19, 2017
    Publication date: October 12, 2017
    Inventors: Richard Compans, Baozhong Wang, Fu Shi Quan, Martin Moore
  • BIOCHEMICALLY STABILIZED HIV-1 ENV TRIMER VACCINE
    Publication number: 20170290907
    Abstract: Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.
    Type: Application
    Filed: May 16, 2017
    Publication date: October 12, 2017
    Inventors: Stephen C. HARRISON, Bing CHEN, Dan H. BAROUCH, Joseph P. NKOLOA, Michael Scott SEAMAN